Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2022

Primary Completion Date

September 14, 2023

Study Completion Date

September 14, 2023

Conditions

PhenylketonuriasPAH DeficiencyPhenylketonuria

Interventions

DRUG

HMI-103

HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene

Trial Locations (2)

Clinic for Special Children, Lancaster

The Community Health Clinic, Topeka